Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.41B P/E - EPS this Y -25.80% Ern Qtrly Grth -
Income -264.08M Forward P/E -7.39 EPS next Y 13.90% 50D Avg Chg -3.00%
Sales 3.5M PEG -0.21 EPS past 5Y - 200D Avg Chg -10.00%
Dividend N/A Price/Book 3.22 EPS next 5Y 23.50% 52W High Chg -31.00%
Recommedations 1.60 Quick Ratio 10.43 Shares Outstanding 85.10M 52W Low Chg 6.00%
Insider Own 0.82% ROA -39.63% Shares Float 84.76M Beta 0.91
Inst Own 105.63% ROE -63.30% Shares Shorted/Prior 9.67M/9.43M Price 20.48
Gross Margin - Profit Margin - Avg. Volume 891,419 Target Price 35.33
Oper. Margin -2,120.46% Earnings Date Oct 31 Volume 706,988 Change -3.03%
About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Syndax Pharmaceuticals, Inc. News
10/09/24 Syndax Pharmaceuticals Inc (SNDX) Q2 2024 Earnings Call Highlights: Strategic Advances and ...
10/04/24 Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
09/18/24 Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease
09/13/24 We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully
09/04/24 Syndax Pharmaceuticals, Inc. (SNDX): This Small-Cap Healthcare Stock Is A Good Buy Right Now
08/15/24 FDA greenlights Incyte and Syndax’s GvHD drug Niktimvo
08/15/24 FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication
04:34 PM Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)
08/12/24 Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia
08/03/24 Despite currently being unprofitable, Syndax Pharmaceuticals (NASDAQ:SNDX) has delivered a 113% return to shareholders over 5 years
08/01/24 Syndax: Q2 Earnings Snapshot
08/01/24 Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update
08/01/24 Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
07/30/24 3 Biotech Stocks That Could Make Your Summer Unforgettable
07/29/24 FDA Delays Decision on Syndax Leukemia Drug; Stock Sinks
07/29/24 Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia
07/25/24 Wall Street Analysts Think Syndax (SNDX) Could Surge 50.26%: Read This Before Placing a Bet
07/25/24 Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024
07/09/24 Wall Street Analysts Believe Syndax (SNDX) Could Rally 67.11%: Here's is How to Trade
06:00 AM Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress
SNDX Chatroom

User Image AZona Posted - 3 days ago

$SNDX strong close 💪 Been here before tho 😅 Let’s see what next week brings 🙏

User Image topstockalerts Posted - 5 days ago

Pre Market Top Gainers $WW $CTCX $ALTM $SNDX $KZR

User Image AlertsAndNews Posted - 5 days ago

Good morning, gappers this morning include $WW $CTCX $ALTM $SNDX $BURU Lets get it!

User Image AZona Posted - 5 days ago

$SNDX 🤔

User Image MewKitty Posted - 6 days ago

$SNDX Anyone following this stock on this board? No activity.

User Image jewell69 Posted - 1 week ago

$SNDX RE ENTRY 252 S ARES

User Image QuantInsider Posted - 1 week ago

Noticed something interesting with $SNDX lately—options volume has jumped up by 3.0x. That’s a pretty big spike and usually means some serious interest is brewing. Makes you wonder if the big players are gearing up for a move or if it’s just another day in the market. What do you all think? Could we be on the brink of something significant, or is it just typical market noise?

User Image AZona Posted - 1 week ago

$SNDX $25 then $30

User Image Jarvis7424 Posted - 1 week ago

$SNDX so strong today 💪🏼

User Image Jarvis7424 Posted - 09/30/24

$SNDX waiting for my $30 🎯

User Image jewell69 Posted - 09/30/24

$SNDX 3/5/24 (6+ MOS) Syndax Pharmaceuticals Mar 05, 2024 Buy Reiterated $30.00 PT BACK ON 3/5: PRICE ABOUT 18.95 (58.81% Upside MS SALVEEN RIC_TER RECC IT.

User Image jewell69 Posted - 09/30/24

$SNDX 09/30/2024 Sell Trade Details SNDX SYNDAX PHARMACEUTICALS I 251 $19.4482 $0.18 $4,881.32 09/26/2024 Buy Trade Details SNDX SYNDAX PHARMACEUTICALS I 251 $18.17 -$4,560.67 90 MINUTES LATER: 19.37

User Image Jarvis7424 Posted - 09/25/24

$SNDX I’ll keep averaging down

User Image jewell69 Posted - 09/24/24

$MTDR buyin 300 on a mkt on close; at time of order 52.15 last, b 52.12 o 52.18 took profits in $SNDX s today 9/24 18.2917 b 9/23 17.99 and s today $MGM 37.35 b 9/23 36.88 lookin 2 add 2 $SRPT down a lot, I am losin

User Image jewell69 Posted - 09/23/24

09/23/2024 Buy Trade Details SNDX SYNDAX PHARMACEUTICALS I 250 $17.99 -$4,497.50 $SNDX BOT JUST NOW 2:33 PM edt

User Image jewell69 Posted - 09/23/24

$SNDX 7/29 PT CUT AT STIFEL Target Price $42.00 $40.00 TRADES: 07/10/2024 Sell Trade Details SNDX SYNDAX PHARMACEUTICALS I 113 $22.61 $0.09 $2,554.84 07/01/2024 Sell Trade Details SNDX SYNDAX PHARMACEUTICALS I 90 $21.5801 $0.06 $1,942.15 05/13/2024 Buy Trade Details SNDX SYNDAX PHARMACEUTICALS I 90 $21.09 -$1,898.10 05/13/2024 Journaled Shares SNDX TDA TRAN - TRANSFER OF SECURITY OR OPTION OUT (SNDX) -113

User Image Jarvis7424 Posted - 09/23/24

$SNDX this is insane

User Image AZona Posted - 09/23/24

$SNDX seems a bit oversold 😅

User Image Bionical Posted - 09/22/24

@GPS_OS_21_vs_SOC_5 I still find it mental how $REPL is 10x this marketcap and $sndx & $KURA are 20x ....

User Image Bionical Posted - 09/22/24

$SLS Sellas marketcap has been at $175million in early 2021 ... why would it be higher with less accomplishments? that's a very low number for a company with such a successful pipeline ... and that would be a 2.25x from here ... sounds like a lot? look at $SNDX or $KURA with their $1.5billion marketcaps ... SLS009 is outperforming their drugs! that would be a 20x from here .. and that's talking about the secondary asset, not even involving GPS ... $XBI

User Image Night_Owl_Biotech Posted - 09/20/24

The attachment notes shares prices over the last 13 weeks (3 months) of the XBI & the 7 commercial-stage oncology focused biopharmas with market caps between $1 & $5B. History suggests these are strong candidates for M&A. A table is also provided that shows market cap to enterprise value for all 7 (using 6/30/2024 balance sheet data where cash has likely been burned since). Also provided are current FY2026 analyst consensus revenue estimates sourced via Seeking Alpha. To the far right, FY2026 revenue multiples are provided. $IOVA & $SWTX trade at the lowest multiple of FY2026 revenue estimates (but were also launched sooner than the others excl IMCR). $IMCR recorded $75MM in Q224 revenues ($300MM annualized) & mgmt suggested Kimmtrak still has legs in mUM. This is not investment advice but IOVA's tail looks encouraging as does $DAWN $SNDX FY26 estimates may include contribution from Revumenib that is not approved yet (PDUFA = 12/26/24).

User Image Stock_Titan Posted - 09/18/24

$SNDX $INCY Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease https://www.stocktitan.net/news/SNDX/incyte-and-syndax-announce-new-england-journal-of-medicine-11a0ohqr4enx.html

User Image Jarvis7424 Posted - 09/18/24

$SNDX wtf?

User Image Polip Posted - 09/18/24

$SNDX are they diluting ATM?

User Image Bionical Posted - 09/17/24

@Engine444 @therightone $SLS with a marketcap of $1Billion (very reasonable and a lot lower than direct competitor $SNDX and $KURA for SLS009) would have the share price at $15.63 at current float. When SLS gets acquired 136.6million shares total with warrants exercised .. MUCH lower than the 7-8x amount that $SMMT has .. a HUGE near 800million shares/warrants .. yet look at their price spike. I’m standing in front of a burning building offering you free fire insurance.

User Image Bionical Posted - 09/16/24

$SLS Pinned harder than a Wi-Fi password on a café chalkboard ... something be brewing. Marketcap should be 15x what it is right now based on SLS009 sofar in comparison to $SNDX and $KURA ... we've got two weeks left before news drops and this sends.

User Image Bionical Posted - 09/16/24

@JakeDelToro I think 1b is way too low a marketcap for a AML treatment halted for efficacy ... the company should be 1b just based on SLS009 sofar, look at its two competition drugs, $SNDX and $KURA ... also 1b would only be like $15 per share unless a lot more warrants get converted to shares

User Image Aigner_Andreas Posted - 1 month ago

#DeathCross $SNDX at 19.12 R7 HiLo 58% T1Y 31 buy 1.7 DIV N/A #Syndax Pha #stocks #trading #finance #market

User Image Jarvis7424 Posted - 1 month ago

$SNDX fucking hell. No reason for this drop

User Image MewKitty Posted - 1 month ago

$SNDX IMHO, dead $$$ until 12/26. Seen this too often with good biotechs + good leadership, like SNDX. Long-term investors need a 2nd PDUFA approval to seal the deal + positive forward guidance from CEO/CFO re earnings. For the vast majority of microcap biotechs, profits or BOs drive SP, ECON 101. GLTA!

Analyst Ratings
Citigroup Buy Aug 16, 24
HC Wainwright & Co. Buy Aug 15, 24
B of A Securities Buy Aug 15, 24
Barclays Overweight Aug 15, 24
JP Morgan Overweight Aug 6, 24
HC Wainwright & Co. Buy Aug 2, 24
B of A Securities Buy Jul 30, 24
HC Wainwright & Co. Buy Jul 29, 24
Jefferies Buy Jun 28, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Morrison Briggs Director Director Aug 09 Sell 18.27 52,855 965,661 17,836 08/10/23
Morrison Briggs Director Director Aug 09 Option 8.77 52,855 463,538 70,691 08/10/23
Morrison Briggs Director Director Jun 09 Sell 21.18 52,855 1,119,469 17,836 06/09/23
Morrison Briggs Director Director Jun 09 Option 7.58 52,855 400,641 70,691 06/09/23
Morrison Briggs Director Director May 09 Sell 21.41 52,855 1,131,626 17,836 05/10/23
Morrison Briggs Director Director May 09 Option 6.38 52,855 337,215 70,691 05/10/23
Ordentlich Peter Chief Scientific Off.. Chief Scientific Officer Feb 15 Sell 25.84 25,000 646,000 02/17/23
Ordentlich Peter Chief Scientific Off.. Chief Scientific Officer Feb 15 Option 6.79 25,000 169,750 17,428 02/17/23
Metzger Michael A Chief Executive Offi.. Chief Executive Officer Feb 06 Sell 27.64 5,959 164,707 17,659 02/08/23
Metzger Michael A Chief Executive Offi.. Chief Executive Officer Feb 06 Option 6.38 5,959 38,018 23,618 02/08/23
Morrison Briggs President, Head of R.. President, Head of R&D Feb 06 Sell 26.83 52,854 1,418,073 17,836 02/08/23
Morrison Briggs President, Head of R.. President, Head of R&D Feb 06 Option 6.38 52,854 337,209 70,690 02/08/23
Ordentlich Peter Chief Scientific Off.. Chief Scientific Officer Jan 31 Sell 28.43 69 1,962 02/03/23
Ordentlich Peter Chief Scientific Off.. Chief Scientific Officer Dec 01 Option 6.37 25,000 159,250 17,465 12/02/22
Ordentlich Peter Chief Scientific Off.. Chief Scientific Officer Dec 01 Sell 25.03 25,000 625,750 265 12/02/22
Morrison Briggs President, Head of R.. President, Head of R&D Sep 19 Option 10.9 173,988 1,896,469 77,485 09/21/22
Morrison Briggs President, Head of R.. President, Head of R&D Sep 19 Sell 23.14 173,988 4,026,082 17,836 09/21/22
Legault Pierre Director Director Aug 05 Option 9.28 24,000 222,720 46,000 08/09/22
Legault Pierre Director Director Aug 05 Sell 23.02 24,000 552,480 32,000 08/09/22
Metzger Michael A Chief Executive Offi.. Chief Executive Officer Jul 25 Option 6.38 31,602 201,621 29,497 07/27/22
Metzger Michael A Chief Executive Offi.. Chief Executive Officer Jul 25 Sell 21.06 31,602 665,538 17,659 07/27/22
Metzger Michael A Chief Executive Offi.. Chief Executive Officer Jul 06 Option 6.38 15,109 96,395 17,759 07/08/22
Metzger Michael A Chief Executive Offi.. Chief Executive Officer Jul 06 Sell 21.04 15,109 317,893 17,659 07/08/22
Morrison Briggs President, Head of R.. President, Head of R&D Apr 01 Option 7.2 73,673 530,446 20,964 04/13/22
Ordentlich Peter Chief Scientific Off.. Chief Scientific Officer Feb 01 Sell 16.65 1,412 23,510 02/03/22
Nolte Alexander Chief Accounting Off.. Chief Accounting Officer Feb 01 Sell 16.65 968 16,117 02/03/22
Legault Pierre Director Director Dec 20 Option 7.48 44,000 329,120 40,000 12/22/21
Legault Pierre Director Director Dec 20 Sell 21.51 44,000 946,440 16,000 12/22/21
Morrison Briggs Chief Executive Offi.. Chief Executive Officer Dec 17 Option 10.9 35,156 383,200 83,492 12/20/21
Morrison Briggs Chief Executive Offi.. Chief Executive Officer Dec 17 Sell 20 35,156 703,120 48,336 12/20/21
Metzger Michael A President and COO President and COO Dec 16 Option 6.98 85,391 596,029 62,659 12/20/21
Metzger Michael A President and COO President and COO Dec 16 Sell 19.67 85,391 1,679,641 17,659 12/20/21
Metzger Michael A President and COO President and COO Dec 13 Option 6.79 36,609 248,575 52,223 12/15/21
Metzger Michael A President and COO President and COO Dec 13 Sell 19.05 36,609 697,401 17,659 12/15/21
Morrison Briggs Chief Executive Offi.. Chief Executive Officer Feb 10 Option 7.2 35,156 253,123 83,492 02/10/21
Morrison Briggs Chief Executive Offi.. Chief Executive Officer Feb 10 Sell 20.55 35,156 722,456 48,336 02/10/21
Ordentlich Peter Chief Scientific Off.. Chief Scientific Officer Nov 25 Option 3.08 29,972 92,314 29,972 11/25/20
Ordentlich Peter Chief Scientific Off.. Chief Scientific Officer Nov 25 Sell 23.27 29,972 697,448 11/25/20
Morrison Briggs Chief Executive Offi.. Chief Executive Officer Nov 12 Option 7.2 80,404 578,909 64,031 11/12/20
Morrison Briggs Chief Executive Offi.. Chief Executive Officer Nov 12 Sell 20.05 80,404 1,612,100 46,565 11/12/20
Metzger Michael A President and COO President and COO Nov 06 Option 7.2 100,000 720,000 117,659 11/06/20
Metzger Michael A President and COO President and COO Nov 06 Sell 20.31 100,000 2,031,000 17,659 11/06/20